

# Simon P L Travis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3683901/publications.pdf>

Version: 2024-02-01

193  
papers

21,586  
citations

20817

60  
h-index

9345

143  
g-index

205  
all docs

205  
docs citations

205  
times ranked

17256  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. <i>Intestinal Research</i> , 2023, 21, 161-167.	2.6	1
2	The gut microbiota as a therapeutic target for obesity: a scoping review. <i>Nutrition Research Reviews</i> , 2022, 35, 207-220.	4.1	14
3	Patient-reported Goals in Inflammatory Bowel Disease: What's the Problem?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 339-340.	1.3	2
4	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. <i>Gut</i> , 2022, 71, 661-664.	12.1	3
5	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000853.	2.7	9
6	Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease Emerging Nations' Consortium. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1004-1015.	2.8	10
7	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	12.8	20
8	Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 273-283.	1.4	6
9	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. <i>Crohn's &amp; Colitis</i> 360, 2022, 4, .	1.1	8
10	Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 836-847.	1.9	21
11	Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. <i>Gut</i> , 2021, 70, 1023-1036.	12.1	58
12	Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 731-739.	2.8	25
13	Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 568-576.	3.7	30
14	Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 1511-1516.	1.6	6
15	P127...Real world effectiveness of ustekinumab for refractory Crohn's disease: a regional experience. , 2021, , .		1
16	P106...Prediction of outcome in acute severe ulcerative colitis " comparison of clinical and endoscopic indices. , 2021, , .		0
17	P107...Changing outcomes in acute severe ulcerative colitis at Oxford in last seven decades. , 2021, , .		0
18	Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. <i>Gut</i> , 2021, 70, 2398-2400.	12.1	9

#	ARTICLE	IF	CITATIONS
19	Overexpression of Cancer-Associated Stem Cell Gene <i>OLFM4</i> in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1316-1327.	1.9	13
20	Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1679-1685.	1.3	14
21	Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis. <i>BMC Gastroenterology</i> , 2021, 21, 132.	2.0	8
22	The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1049-1055.	1.5	2
23	Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2021, 37, 1891-1900.	1.9	10
24	Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 456-473.	1.8	79
25	High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis. <i>Intestinal Research</i> , 2021, 19, 438-447.	2.6	9
26	IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. <i>Nature Medicine</i> , 2021, 27, 1970-1981.	30.7	117
27	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	28.9	262
28	Gut microbiota: sculptors of the intestinal stem cell niche in health and inflammatory bowel disease. <i>Gut Microbes</i> , 2021, 13, 1990827.	9.8	32
29	OFR-10...Admission model for intensification of therapy in acute severe colitis (ADMIT-ASC). , 2021, , ,		0
30	Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 390-399.	3.7	4
31	Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. <i>Nature Communications</i> , 2021, 12, 6702.	12.8	13
32	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	1.5	6
33	Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 747-748.	3.7	0
34	Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 142-147.	1.3	27
35	The impact of intestinal transplantation on quality of life. <i>Clinical Nutrition</i> , 2020, 39, 1958-1967.	5.0	12
36	IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1-3.	1.3	6

#	ARTICLE	IF	CITATIONS
37	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 192-204.	1.3	45
38	Is Crohn's Disease a Rightly Used Eponym?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 867-871.	1.3	1
39	Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 149-157.	3.7	31
40	Loss of IL-10 signaling in macrophages limits bacterial killing driven by prostaglandin E2. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	51
41	Prevalence and long-term outcome of subclinical primary sclerosing cholangitis in patients with ulcerative colitis. <i>Liver International</i> , 2020, 40, 2744-2757.	3.9	13
42	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020, 69, 658-664.	12.1	21
43	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1446-1461.	1.3	25
44	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	1.3	126
45	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	1.9	27
46	Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. <i>Nature Communications</i> , 2020, 11, 995.	12.8	37
47	Short- and long-term outcomes of strictureplasty for obstructive Crohn's disease. <i>Colorectal Disease</i> , 2020, 22, 1159-1168.	1.4	8
48	Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. <i>Rheumatology</i> , 2020, 59, 2166-2168.	1.9	17
49	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 365-376.	17.8	37
50	Does Smoking Cessation Reduce Surgical Recurrence After Primary Ileocolic Resection for Crohn's Disease?. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 200-206.	1.3	8
51	Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. <i>World Journal of Gastroenterology</i> , 2020, 26, 4428-4441.	3.3	16
52	Interfering with leukocyte trafficking in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101617.	2.4	18
53	Autologous stem cell transplantation in refractory Crohn's disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019, 19, 82.	2.0	17
54	Visceral Adipose Tissue Is Associated With Strictureing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 592-600.	1.9	39

#	ARTICLE	IF	CITATIONS
55	Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 424-430.	1.3	54
56	Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e62-e63.	1.9	0
57	Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. <i>Health Technology Assessment</i> , 2019, 23, 1-162.	2.8	10
58	Improving the quality of care for inflammatory bowel disease. <i>Intestinal Research</i> , 2019, 17, 45-53.	2.6	17
59	Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. <i>Intestinal Research</i> , 2019, 17, 365-374.	2.6	12
60	Diagnostic Yield of Dysplasia in Polyp-adjacent Biopsies for Patients with Inflammatory Bowel Disease: A Cross-sectional Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 670-676.	1.3	19
61	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 562-574.	6.0	71
62	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 408-418.	1.3	102
63	Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 305-316.	8.1	31
64	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	12.1	108
65	Endoscopy in Inflammatory Bowel Disease: Western Perspective—Europe. , 2018, , 275-282.		0
66	Limited uptake of ulcerative colitis treatment target recommendations in real-world practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 599-607.	2.8	32
67	Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 615-622.	2.8	21
68	What's app? Electronic health technology in inflammatory bowel disease. <i>Intestinal Research</i> , 2018, 16, 366.	2.6	22
69	Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1438-1447.	1.3	12
70	Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia. <i>Nutrients</i> , 2018, 10, 1192.	4.1	53
71	Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 905-919.	1.3	20
72	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1097-1103.	1.3	29

#	ARTICLE	IF	CITATIONS
73	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	1.0	29
74	Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 548-558.	8.1	143
75	Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?. <i>Intestinal Research</i> , 2018, 16, 209.	2.6	12
76	Analysis of the Gut Microbiome of Rural and Urban Healthy Indians Living in Sea Level and High Altitude Areas. <i>Scientific Reports</i> , 2018, 8, 10104.	3.3	104
77	Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1326-1337.	1.3	35
78	Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1151-1157.	1.3	22
79	Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2747-2753.	2.3	3
80	IBD2020 global forum: results of an international patient survey on quality of care. <i>Intestinal Research</i> , 2018, 16, 537-545.	2.6	20
81	Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. <i>Intestinal Research</i> , 2018, 16, 69.	2.6	10
82	Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw159.	1.3	19
83	Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw174.	1.3	12
84	Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw187.	1.3	40
85	Development and validation of the Nancy histological index for UC. <i>Gut</i> , 2017, 66, 43-49.	12.1	322
86	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 801-813.	3.7	106
87	Th1 and Innate Lymphoid Cells Accumulate in Primary Sclerosing Cholangitis-associated Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1124-1134.	1.3	43
88	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 3-15.	3.7	97
89	Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1309-1316.	1.3	46
90	Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor- $\alpha$ neutralizing therapy in patients with inflammatory bowel disease. <i>Nature Medicine</i> , 2017, 23, 579-589.	30.7	571

#	ARTICLE	IF	CITATIONS
91	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	13.7	633
92	Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1317-1325.	1.3	35
93	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	8.1	70
94	Editorial: gut selective immunosuppression is it a double edged sword? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 374-374.	3.7	0
95	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	1.3	19
96	Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 607-620.e15.	2.9	77
97	The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 251-256.	1.5	19
98	Central Endoscopy Reading in Inflammatory Bowel Diseases: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S542-S547.	1.3	18
99	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 273-282.	8.1	91
100	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e121-e122.	4.4	3
101	Current best practice for disease activity assessment in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 567-579.	17.8	169
102	Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 15-24.	8.1	176
103	Swallowing anti-TNF in Ulcerative Colitis: Potentially More Gain Than Pain. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 629-630.	1.3	0
104	Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. <i>Gut</i> , 2016, 65, 408-414.	12.1	339
105	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	1.3	39
106	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	26
107	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 601-606.	1.3	81
108	Association Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 376-381.	1.3	104

#	ARTICLE	IF	CITATIONS
109	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	7.4	136
110	Response to Villanacci et. al.. Journal of Crohn's and Colitis, 2015, 9, 429-429.	1.3	0
111	Endoscopic Disease Activity in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2015, 17, 50.	2.5	13
112	Toxic dilatation of the colon. Medicine, 2015, 43, 171-173.	0.4	1
113	Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. The Cochrane Library, 2015, , .	2.8	2
114	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. Journal of Crohn's and Colitis, 2015, 9, 607-616.	1.3	50
115	Introducing Vedolizumab to Clinical Practice: Who, When, and How?. Journal of Crohn's and Colitis, 2015, 9, 356-366.	1.3	53
116	Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet, The, 2015, 386, 137-144.	13.7	207
117	Does Disease Extent Matter when Scoring the UCEIS?. Journal of Crohn's and Colitis, 2015, 9, 694-694.	1.3	4
118	Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open, 2015, 5, e007230-e007230.	1.9	57
119	Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea. Human Molecular Genetics, 2015, 24, 6614-6623.	2.9	111
120	Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. Journal of Crohn's and Colitis, 2015, 9, 738-746.	1.3	31
121	Conventional drug therapy for inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2015, 50, 90-112.	1.5	57
122	'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?. Intestinal Research, 2015, 13, 227.	2.6	19
123	Systematic review: Histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. Journal of Crohn's and Colitis, 2014, 8, 1582-1597.	1.3	235
124	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut, 2014, 63, 433-441.	12.1	222
125	Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2014, 12, 1981-1990.	4.4	24
126	The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease. Gastroenterology, 2014, 147, 990-1007.e3.	1.3	559



#	ARTICLE	IF	CITATIONS
127	Acute variceal haemorrhage in the United Kingdom: Patient characteristics, management and outcomes in a nationwide audit. <i>Digestive and Liver Disease</i> , 2014, 46, 419-426.	0.9	81
128	Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 166-171.	1.3	23
129	Poor Outcomes in Hospitalized Patients With Gastrointestinal Bleeding: Impact of Baseline Risk, Bleeding Severity, and Process of Care. <i>American Journal of Gastroenterology</i> , 2014, 109, 1603-1612.	0.4	21
130	METRIC (MREnterography or ulTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. <i>BMC Gastroenterology</i> , 2014, 14, 142.	2.0	36
131	Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2014, 24, 367-378.	1.4	101
132	Unexplained gastrointestinal symptoms: Think mitochondrial disease. <i>Digestive and Liver Disease</i> , 2014, 46, 1-8.	0.9	29
133	Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 662-670.	1.3	45
134	Comparing disease activity indices in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 318-325.	1.3	89
135	Assessment of Disease Activity in Ulcerative Colitis. , 2014, , 345-357.		0
136	Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 144, S-763.	1.3	3
137	Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e449-e456.	1.3	45
138	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 149-157.e2.	1.3	196
139	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	1.3	422
140	Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. <i>Transfusion</i> , 2013, 53, 1069-1076.	1.6	38
141	554 Correlation Between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Outcomes in Acute Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 144, S-102.	1.3	5
142	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. <i>Gastroenterology</i> , 2013, 145, 987-995.	1.3	354
143	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012, 61, 535-542.	12.1	463
144	Mucosal healing in inflammatory bowel diseases: a systematic review. <i>Gut</i> , 2012, 61, 1619-1635.	12.1	673

#	ARTICLE	IF	CITATIONS
145	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , 2012, 61, 1693-1700.	12.1	1,295
146	The future of inflammatory bowel disease management: Combining progress in trial design with advances in targeted therapy. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S250-S259.	1.3	23
147	Once-Daily Budesonide MMX <sup>®</sup> Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study. <i>Gastroenterology</i> , 2012, 143, 1218-1226.e2.	1.3	213
148	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 991-1030.	1.3	1,106
149	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 965-990.	1.3	715
150	Assessing disease activity in patients with ulcerative colitis. <i>Gastroenterology and Hepatology</i> , 2012, 8, 751-4.	0.1	7
151	Conventional Medical Management of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, 1827-1837.e2.	1.3	200
152	IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. <i>Journal of Experimental Medicine</i> , 2011, 208, 1127-1133.	8.5	572
153	Does it all ADA up? Adalimumab for ulcerative colitis. <i>Gut</i> , 2011, 60, 741-742.	12.1	8
154	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. <i>American Journal of Gastroenterology</i> , 2011, 106, 199-212.	0.4	356
155	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1594-1602.	0.4	71
156	Colon salvage therapy for acute severe colitis: cyclosporine or infliximab?. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 358-362.	2.3	12
157	Induction of remission with oral budesonide MMX <sup>®</sup> (9 mg) tablets in patients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S20.	1.9	3
158	Review article: defining remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 113-124.	3.7	180
159	Exposure to hookworms in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1248-1249.	3.7	4
160	Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. <i>Transfusion</i> , 2011, 51, 1940-1948.	1.6	25
161	Development of the Crohn's disease digestive damage score, the Lönnemann score. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1415-1422.	1.9	496
162	Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. <i>Gut</i> , 2011, 60, 3-9.	12.1	93

#	ARTICLE	IF	CITATIONS
163	Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. <i>British Journal of Surgery</i> , 2010, 97, 404-409.	0.3	202
164	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 63-101.	1.3	695
165	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 28-62.	1.3	1,247
166	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 7-27.	1.3	1,050
167	The pattern and outcome of acute severe colitis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 431-437.	1.3	276
168	Long-term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992-1993 cohort. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 823-828.	1.9	70
169	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1599-1604.	1.9	93
170	An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 32-37.	1.3	10
171	An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 168-174.	1.3	9
172	The role of CMV in steroid-resistant ulcerative colitis: A systematic review. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 141-148.	1.3	60
173	The role of blood transfusion in the management of upper and lower intestinal tract bleeding. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 355-371.	2.4	14
174	Foreword from the Chairman. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, v-v.	3.7	1
175	The Management of Acute Severe Colitis: ACPGIB Position Statement. <i>Colorectal Disease</i> , 2008, 10, 8-29.	1.4	45
176	Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 170-180.	1.3	36
177	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 1-23.	1.3	470
178	Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 337-342.	1.3	31
179	Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. <i>Trials</i> , 2007, 8, 17.	1.6	113
180	New thinking: theory vs practice. A case study illustrating evidence-based therapeutic decision making. <i>Colorectal Disease</i> , 2006, 8, 25-29.	1.4	4

#	ARTICLE	IF	CITATIONS
181	Review article: induction therapy for patients with active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 10-16.	3.7	40
182	European evidence based consensus on the diagnosis and management of Crohn's disease: current management. <i>Gut</i> , 2006, 55, i16-i35.	12.1	533
183	Conduct of Clinical Trials in UC. <i>American Journal of Gastroenterology</i> , 2006, 101, S429-S430.	0.4	4
184	Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 713-719.	1.9	103
185	Advances in therapeutic approaches to ulcerative colitis and crohn's disease. <i>Current Gastroenterology Reports</i> , 2005, 7, 475-484.	2.5	21
186	What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2005, 2, 564-565.	1.7	5
187	Dose escalation of 5ASA: does it work?. <i>Digestive and Liver Disease</i> , 2005, 37, 82-84.	0.9	2
188	The management of mild to severe acute ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 88-92.	3.7	30
189	Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2004, 53, v1-v16.	12.1	914
190	5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study. <i>Gastroenterology</i> , 2004, 126, 1733-1739.	1.3	154
191	Predicting outcome in severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2004, 36, 448-449.	0.9	18
192	Recent advances in immunomodulation in the treatment of inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 215-218.	1.6	14
193	Which 5-ASA?. <i>Gut</i> , 2002, 51, 548-549.	12.1	8